Virtu Financial LLC Purchases Shares of 10,080 Acelyrin, Inc. (NASDAQ:SLRN)

Virtu Financial LLC acquired a new position in shares of Acelyrin, Inc. (NASDAQ:SLRN) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,080 shares of the company’s stock, valued at approximately $50,000.

A number of other large investors have also recently made changes to their positions in the stock. HighTower Advisors LLC purchased a new stake in Acelyrin in the third quarter valued at approximately $50,000. Principal Financial Group Inc. purchased a new stake in shares of Acelyrin in the 2nd quarter valued at $49,000. SG Americas Securities LLC acquired a new stake in shares of Acelyrin in the second quarter worth $51,000. Nisa Investment Advisors LLC raised its holdings in shares of Acelyrin by 58,570.8% during the second quarter. Nisa Investment Advisors LLC now owns 14,081 shares of the company’s stock worth $62,000 after purchasing an additional 14,057 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in Acelyrin during the third quarter valued at $77,000. 87.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on SLRN shares. HC Wainwright reiterated a “neutral” rating and set a $8.00 price objective on shares of Acelyrin in a research note on Wednesday, December 11th. Wells Fargo & Company reduced their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th.

Acelyrin Stock Performance

Shares of Acelyrin stock opened at $3.15 on Friday. The firm has a 50-day simple moving average of $5.01 and a two-hundred day simple moving average of $4.97. Acelyrin, Inc. has a fifty-two week low of $3.11 and a fifty-two week high of $8.89. The company has a market cap of $316.03 million, a P/E ratio of -1.28 and a beta of 1.61.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.